Sandoz Omnitrope NDA Is Test For Follow-On Biologics; Pfizer Says No
Executive Summary
Sandoz' pending NDA for Omnitrope appears ripe for an FDA decision
You may also be interested in...
Governors Take Aim At FDA For Not Releasing Follow-On Biologics Guidances
A bipartisan group of four governors are accusing FDA of violating the Administrative Procedure Act by not issuing guidance documents on therapeutically equivalent versions of insulin and human growth hormone products
Governors Take Aim At FDA For Not Releasing Follow-On Biologics Guidances
A bipartisan group of four governors are accusing FDA of violating the Administrative Procedure Act by not issuing guidance documents on therapeutically equivalent versions of insulin and human growth hormone products
FDA Clears Omnitrope; Product Is Not The Process, But Nor Is It A Pathway
Sandoz' approval for the first follow-on version of a human growth hormone product relies on data from a Phase III clinical program that studied 89 pediatric patients